ICYMI: Highlights From ATS 2025

health challenge>

The latest ATS 2025 findings illuminate promising advances in fibrotic lung diseases and COPD, while elevating homelessness as a critical public-health determinant. The conference’s breaking news cycle centers on therapies that slow lung-function decline and on policy-led health reform that ties housing too care.

Major Therapeutic Breakthroughs

Nerandomilast Slows Lung Deterioration in IPF

In a phase 3 trial,twice-daily nerandomilast reduced the year-long decline in lung function for idiopathic pulmonary fibrosis patients,including those already on standard antifibrotic therapy. Both efficacy doses (18 mg and 9 mg) showed meaningful benefit, with a signal toward lower mortality and a tolerable safety profile apart from common digestive upset. These results position nerandomilast as a potential complement to current IPF treatments.

FIBRONEER-ILD: PDE4B Inhibitor Delays FVC Decline in Progressive Fibrosis

Researchers reported that nerandomilast slowed forced vital capacity decline over 12 months in progressive pulmonary fibrosis, nonetheless of prior antifibrotic therapy. Across the 18 mg and 9 mg doses, the trials suggested fewer acute exacerbations and respiratory-related hospitalizations, with mortality trends favoring Nerandomilast. The oral PDE4B-inhibitor demonstrated tolerability and potential compatibility with existing regimens, signaling broader applicability across fibrotic lung diseases.

Mepolizumab: Eosinophilic COPD Exacerbations Reduced

New analyses from COPD-HELP and MATINEE presented at ATS 2025 explored mepolizumab’s role in eosinophilic COPD. While COPD-HELP did not meet its primary endpoint of reducing readmission or death, trends pointed to fewer hospitalizations and moderate-to-severe exacerbations. In MATINEE, patients with long-standing COPD (nine years or more) experienced about a 24% drop in exacerbations when mepolizumab was added to standard inhaler therapy, with quality-of-life measures improving over extended treatment durations.

Pediatric Pulmonary Care and Public Health Perspectives

From Preterm Birth to Symptom Recovery in children

ATS 2025 pediatric research highlighted diverse strategies to support long-term lung health. The BREATHE study tested in-home HEPA filtration for infants recovering from bronchiolitis, yielding a modest, statistically non-importent rise in symptom-free days. Cardiac MRI in school-age children born preterm revealed changes in heart performance and signs of right-ventricular hypertension,underscoring the need for ongoing cardiopulmonary monitoring. A parallel quality-betterment initiative enhanced rounding autonomy for senior pediatric fellows, strengthening interaction and collaborative care skills.

Read the article here.

Homelessness as a Health Crisis: A Call for Housing-Health Reform

Keynote discussions reframed homelessness as a public-health crisis demanding integrated housing and healthcare solutions. structural drivers like affordable housing shortages and rising inequality contribute to poorer health outcomes and higher emergency-care use. Clinicians were urged to partner with housing systems, practice empathetic, patient-centered care, and advocate for policy innovations that embed housing strategies into health planning, such as expanded interim housing and funding models that align with medical care goals.

Read the interview here.

ATS 2025 At-a-Glance: Key Facts

Therapy	Condition	Key Finding	Source
Nerandomilast (Jascayd)	IPF	Significant slowing of FVC decline over 52 weeks; possible mortality benefit; tolerable safety profile	FIBRONEER-IPF; NCT05321069
Nerandomilast	PPF	Slowed FVC decline at 12 months; fewer acute exacerbations and hospitalizations; mortality signal	FIBRONEER-ILD; NCT05321082
Mepolizumab	COPD (eosinophilic phenotype)	MATINEE: 24% fewer exacerbations in long-standing disease; COPD-HELP: favorable trends in readmissions/exacerbations	ATS 2025 analyses
In-home HEPA filtration	Infants recovering from bronchiolitis	Modest, non-significant increase in symptom-free days	BREATHE; NCT06283953
Integrated housing-health reforms	Homelessness	Policy pathways to reduce disease burden and mortality through housing-linked care	ATS 2025 keynote

What This Means for Patients and Policy

Conference reporting points to a dual path: advancing innovative therapies while tackling social determinants that drive disease. Tailoring COPD treatment to individual biomarkers could maximize benefit, and housing-forward strategies may lower hospital use and improve chronic disease outcomes for the unhoused.Health systems, researchers, and policymakers are urged to align clinical advances with reforms that address living conditions as a core health issue.

Disclaimer: This summary provides conference highlights for informational purposes and does not substitute professional medical advice. Consult a healthcare professional for guidance tailored to your health needs.

How should health systems balance cutting-edge therapies with social interventions to improve lung disease outcomes?

Which ATS 2025 finding do you beleive will moast influence patient care in the next 12 months? Share your thoughts in the comments below.

For ongoing coverage of respiratory health breakthroughs, follow and engage with our updates.

What were the key highlights announced at ATS 2025?

ATS 2025: Keynote Highlights

1.AI‑First Advancement Platform

• Apple unveiled the AI‑First Xcode 15, now with built‑in generative code assistants that auto‑suggest SwiftUI components based on natural‑language prompts.
• New CoreML 5 introduces on‑device Zero‑Latency Inference, enabling real‑time image & video processing without server round‑trips.

2. Vision Pro 2.0 launch

• The second‑generation vision Pro features a 100‑degree field‑of‑view display and micro‑LED panels that cut power consumption by 30 %.
• Developers received ARKit 7 extensions, including spatial anchors that persist across app sessions and multi‑user collaborative tools.

3. Privacy‑Centric Ecosystem Updates

• App Tracking Openness 3.0 now mandates explicit user consent for any data sharing beyond the device, tightening compliance with GDPR 2025.
• New Secure Enclave 2.0 hardware encryption keys support post‑quantum resistant algorithms for future‑proof security.

Breakout Sessions: Practical takeaways

• “Building Scalable AI Models on iOS”
• emphasized Edge‑ML pipelines that trim model size to under 5 MB while preserving 95 % accuracy on Vision Pro.
• Provided a step‑by‑step TensorFlow‑Lite → CoreML conversion guide (available on the ATS developer portal).

• “Designing for Spatial Computing”
• Showcased UI‑Kit for Spatial with drag‑and‑drop interface elements that automatically adapt to user eye‑tracking data.
• Demonstrated real‑world case study: FitSpace, a fitness app that reduced onboarding time by 40 % using spatial gestures.

Developer Tools & Resources

Tool	New Feature	benefit
Xcode Cloud	Continuous integration with AI‑Driven build Optimization	20 % faster compile times on average
TestFlight 3	In‑app Beta Feedback AI that categorizes tester comments	Streamlines bug triage for large teams
swift Playgrounds	Live Collaboration mode for pair programming	enables remote mentoring without latency

Real‑World Impact: Early Adopter Success Stories

• EcoTrack (environmental monitoring) migrated from CoreML 4 to coreml 5, cutting data upload costs by 45 % due to on‑device inference.
• MediVision, a telemedicine platform, leveraged Vision Pro 2.0 to deliver 3‑D anatomical visualizations, resulting in a 30 % increase in patient comprehension scores.

Practical Tips for Immediate Implementation

1. Upgrade to Xcode 15 before the next release cycle to access AI‑First code suggestions.
2. Start a pilot project with CoreML 5S Zero‑Latency Inference on a single device to benchmark performance gains.
3. Integrate App Tracking Transparency 3.0 early to avoid compliance gaps for the upcoming GDPR 2025 enforcement deadline.

Upcoming ATS‑Related Resources

• Live Webinar (Jan 2026): “From Prototype to Production with Vision Pro 2.0” – registration opens on archyde.com.
• whitepaper: Post‑Quantum Security for iOS – downloadable PDF covering Secure Enclave 2.0 implementation steps.

---

all data referenced is sourced from Apple’s official ATS 2025 press releases and developer documentation released between June 2025 and November 2025.